Zydus Lifesciences rises on signing pact with Synthon BV
Zydus Lifesciences is currently trading at Rs. 944.60, up by 10.40 points or 1.11% from its previous closing of Rs. 934.20 on the BSE.
The scrip opened at Rs. 939.45 and has touched a high and low of Rs. 954.20 and Rs. 936.80 respectively. So far 12543 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 845.10 on 14-Feb-2024.
Last one week high and low of the scrip stood at Rs. 1012.90 and Rs. 920.95 respectively. The current market cap of the company is Rs. 95008.61 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.18% and 6.84% respectively.
Zydus Lifesciences has signed an exclusive development, licensing, supply and commercialisation pact with Synthon BV of the Netherlands for a novel oncology product for an undisclosed target. The novel 505(B)(2) oncology product is likely to be filed in 2026 and will offer additional strengths that are intended to provide reduced pill burden, flexibility for dose adjustment and enhanced patient compliance.
Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product. Zydus will be responsible for the NDA submission and commercialisation of the product in the US.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
